Avalyn Pharma Inc. Company Profile
NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:58 PM ET
Avalyn Pharma at a glance
Avalyn Pharma Inc. (NASDAQ: AVLN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Avalyn Pharma is led by Ms. Lyn Baranowski and employs about 55 people. The company's shares have traded publicly since 2026.
At a market capitalization of $1.13 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001540171, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Avalyn Pharma do?
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Avalyn Pharma Inc.
- Ticker
- NASDAQ: AVLN
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Lyn Baranowski
- Employees
- 55
- Headquarters
- 105 W First Street, Boston, MA, United States
- Phone
- (206) 707-0340
- Website
- avalynpharma.com
- IPO year
- 2026
- Market cap
- $1.13B
- SEC CIK
- 0001540171
Companies similar to Avalyn Pharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JANXJanux Therapeutics Inc. | 18.36 | +2.46% | $1.12B | vs AVLN |
| BCAXBicara Therapeutics Inc. | 16.91 | +2.98% | $1.12B | vs AVLN |
| TRAXFirst Tracks Biotherapeutics Inc. | 31.99 | +4.56% | $1.14B | vs AVLN |
| LBRXLB Pharmaceuticals Inc | 34.41 | +0.73% | $1.11B | vs AVLN |
| HROWHarrow Inc. | 30.60 | -0.07% | $1.15B | vs AVLN |
| AMPHAmphastar Pharmaceuticals Inc. | 26.02 | +1.88% | $1.11B | vs AVLN |
| MNKDMannKind Corporation | 3.44 | -0.43% | $1.10B | vs AVLN |
| NBTXNanobiotix S.A. ADR | 23.14 | -6.01% | $1.18B | vs AVLN |